news
New amyloidosis drugs extend survival for rare protein-misfolding diseases
A Lancet editorial highlights a decade of progress in amyloidosis treatments. Since 2018, new therapies have increased the 10-year survival rate for some subtypes from 5% to 20%. This group of rare disorders involves misfolded protein deposits leading to progressive organ failure.
A Lancet editorial highlights a decade of progress in amyloidosis treatments. Since 2018, new therapies have increased the 10-year survival rate for some subtypes from 5% to 20%. This group of rare disorders involves misfolded protein deposits leading to progressive organ failure.
The architecture take
This isn't just about a rare disease; it's a giant neon sign for what's coming in the longevity space. When we talk about "misfolded proteins," we're usually thinking Alzheimer's or Parkinson's, right? But amyloidosis shows us what targeting these specific protein deposits can achieve. The mechanism here is literally cleaning house at a cellular level, preventing organ-damaging buildup. A 400% increase in 10-year survival for a previously rapidly fatal condition? That's a huge win, and it proves that specific molecular interventions can dramatically alter disease trajectory, not just manage symptoms. You should see this as foreshadowing for a future where we directly address protein aggregation in other aging-related conditions, not just a pharma success story for a niche illness. Watch for more biotech plays to spin up targeting protein quality control, because this is what "biological age reversal" actually looks like.